Loading…
Molbio Diagnostics (MOLBIO)₹1,336−1.78%Medical Equipment & Supplies
In the Jun 2026 quarter (consolidated), Molbio Diagnostics reported sales of ₹407 Cr, up 308.2% from Jun 2025, and net profit of ₹53.12 Cr. For the year to Mar 2026, sales were ₹1,442 Cr and net profit ₹164 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales | 99.62 | 560 | 407 |
| Expenses | 116 | 403 | 309 |
| Operating Profit | −15.96 | 159 | 101 |
| OPM % | −16.1% | 28.0% | 24.9% |
| Other Income | 0.99 | 4.99 | 2.99 |
| Interest | 3.99 | 11.99 | 10.99 |
| Depreciation | 12.03 | 20.04 | 17.04 |
| Profit before tax | −30.87 | 131 | 75.77 |
| Tax % | −23.1% | 26.9% | 30.9% |
| Net Profit | −24.06 | 96.24 | 53.12 |
| EPS (Rs) | −10.52 | 8.07 | 5.22 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 835 | 1,017 | 1,442 |
| Expenses | 604 | 762 | 1,130 |
| Operating Profit | 233 | 259 | 319 |
| OPM % | 27.9% | 25.9% | 22.0% |
| Other Income | −48.90 | −3.99 | 8.98 |
| Interest | 13.99 | 17.98 | 32.99 |
| Depreciation | 41.12 | 45.13 | 64.14 |
| Profit before tax | 130 | 193 | 230 |
| Tax % | 36.0% | 28.9% | 28.9% |
| Exceptional items | −25.94 | −6.98 | −0.99 |
| Net Profit | 84.30 | 139 | 164 |
| EPS (Rs) | 453.35 | 64.43 | 14.79 |
| Dividend payout % | 0.0% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 2.00 | 2.00 | 10.99 |
| Reserves | 819 | 964 | 1,156 |
| Borrowings | 184 | 147 | 451 |
| Other Liabilities | 212 | 348 | 498 |
| Total Liabilities | 1,218 | 1,461 | 2,117 |
| Fixed Assets | 289 | 290 | 535 |
| CWIP | 1.99 | 26.90 | 10.96 |
| Investments | 5.98 | 45.86 | 5.98 |
| Other Assets | 921 | 1,100 | 1,564 |
| Inventories | 315 | 437 | 450 |
| Trade receivables | 425 | 272 | 409 |
| Cash & equivalents | 21.92 | 129 | 366 |
| Total Assets | 1,218 | 1,461 | 2,117 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 10.01 | 287 | 50.05 |
| Cash from investing activity | — | — | — | −45.05 | −123 | −54.08 |
| Cash from financing activity | — | — | — | −32.06 | −26.02 | 276 |
| Net cash flow | — | — | — | −67.17 | 138 | 274 |
| Capex | 134 | 64.14 | 14.04 | 16.04 | 55.12 | 50.14 |
| Free cash flow | — | — | — | −6.99 | 232 | 0.99 |
| CFO / OP % | — | — | — | 23.1% | 141.1% | 38.1% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 185 | 96 | 102 |
| Inventory days | 338 | 384 | 285 |
| Days payable | 101 | 203 | 126 |
| Cash conversion cycle | 423 | 278 | 261 |
| Working capital days | 201 | 129 | 117 |
| ROCE % | — | 20.9% | 17.9% |
For the Jun 2026 quarter, Molbio Diagnostics reported sales of ₹407 Cr, up 308.2% year on year and net profit of ₹53.12 Cr. The operating margin was 24.9%.
Molbio Diagnostics' sales for the year to Mar 2026 were ₹1,442 Cr.
Net profit for the year to Mar 2026 was ₹164 Cr. Earnings per share over the same trailing period were ₹14.79.
Molbio Diagnostics reported borrowings of ₹451 Cr at Mar 2026, against cash and equivalents of ₹366 Cr.
Cash from operations was ₹50.05 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0.99 Cr.